{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:53:23Z","timestamp":1783043603066,"version":"3.54.6"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>A total of 2361 ceftazidime\u2013avibactam-resistant non-carbapenemase-producing (CP) carbapenem-resistant Enterobacterales (CRE) isolates were identified, accounting for 45.8% of global non-CP-CRE (n\u200a=\u200a5156) and 3.0% of all Enterobacterales isolates (n\u200a=\u200a78\u200a371) during 2020\u201323. The high prevalence of non-CP-CRE resistant to ceftazidime\u2013avibactam prompted investigations into alternative antibiotics for the effective management of ceftazidime\u2013avibactam-resistant non-CP-CRE infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the susceptibility breakpoints for Enterobacterales recommended by CLSI 2025 (for ceftazidime\u2013avibactam, amikacin and meropenem\u2013vaborbactam), EUCAST 2025 (for aztreonam\u2013avibactam, colistin) and the US FDA (for tigecycline), susceptibility data of key antibiotics against global ceftazidime\u2013avibactam-resistant non-CP-CRE isolates were extracted from the 2020\u201323 Antimicrobial Testing Leadership and Surveillance database. Additionally, data on genes encoding ESBL and plasmid-mediated AmpC enzymes were also analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In vitro susceptibility rates of global ceftazidime\u2013avibactam-resistant non-CP-CRE isolates to aztreonam\u2013avibactam, colistin and tigecycline all exceeded 86%. In contrast, non-susceptibility rates to amikacin and meropenem\u2013vaborbactam were 78.7% and 94.8%, respectively. These high non-susceptibility rates for amikacin and meropenem\u2013vaborbactam persisted regardless of region, infection source or species [Klebsiella pneumoniae (n\u200a=\u200a1576), Escherichia coli (n\u200a=\u200a388) and potentially chromosomal AmpC hyperproducers (n\u200a=\u200a337)]. The prevalence of blaCTX-M-15 (the predominant ESBL) was closely correlated with amikacin non-susceptibilities across all three species groups (r\u200a=\u200a0.901; P\u200a=\u200a0.286).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on the data from this study, poor in vitro susceptibility rates for amikacin and meropenem\u2013vaborbactam against contemporary ceftazidime\u2013avibactam-resistant non-CP-CRE were observed. In contrast, aztreonam\u2013avibactam, colistin and tigecycline appear to be reasonable options for the management of infections caused by ceftazidime\u2013avibactam-resistant non-CP-CRE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf375","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:45:07Z","timestamp":1758627907000},"page":"3345-3351","source":"Crossref","is-referenced-by-count":1,"title":["Global susceptibility profiles and potential resistance mechanisms of ceftazidime\u2013avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020\u201323 data from the Antimicrobial Testing Leadership and Surveillance"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center , Tainan ,","place":["Taiwan"]},{"name":"School of Medicine, College of Medicine, National Sun Yat-sen University , Kaohsiung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Department of Hospitalist, Far Eastern Memorial Hospital , New Taipei City ,","place":["Taiwan"]},{"name":"General Education Center, Lunghwa University of Science and Technology , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Jie","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of General Surgery, Department of Surgery, Min-Sheng General Hospital , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-tsung","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy and Health Care, Tajen University , Pingtung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chuen","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy and Health Care, Tajen University , Pingtung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shio-Shin","family":"Jean","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy and Health Care, Tajen University , Pingtung ,","place":["Taiwan"]},{"name":"Departments of Internal Medicine and Critical Care Medicine, Min-Sheng General Hospital , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2025120206225485300_dkaf375-B1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41598-023-51118-9","article-title":"Comparison of mortality rates in patients with carbapenem-resistant Enterobacterales bacteremia according to carbapenemase production: a multicenter propensity-score matched study","volume":"14","author":"Baek","year":"2024","journal-title":"Sci Rep"},{"key":"2025120206225485300_dkaf375-B2","doi-asserted-by":"publisher","first-page":"107500","DOI":"10.1016\/j.ijantimicag.2025.107500","article-title":"Geographic variations in distributions of carbapenemase-encoding genes, susceptibilities, and minimum inhibitory concentrations of inpatient meropenem-resistant Enterobacterales to ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam across four global regions: 2020\u20132022 data from the antimicrobial testing leadership and surveillance","volume":"66","author":"Jean","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"2025120206225485300_dkaf375-B3","doi-asserted-by":"publisher","first-page":"106380","DOI":"10.1016\/j.jinf.2024.106380","article-title":"Distributions of plasmidic genes encoding extended-spectrum and AmpC \u03b2-lactamases, and susceptibilities of global non-carbapenemase-producing meropenem-resistant Enterobacterales to ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam, 2017\u20132022","volume":"90","author":"Jean","year":"2025","journal-title":"J Infect"},{"key":"2025120206225485300_dkaf375-B4","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirty-Fifth Edition: M100","author":"CLSI","year":"2025"},{"key":"2025120206225485300_dkaf375-B5","author":"EUCAST"},{"key":"2025120206225485300_dkaf375-B6","author":"FDA"},{"key":"2025120206225485300_dkaf375-B7","doi-asserted-by":"publisher","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225485300_dkaf375-B8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jgar.2021.01.010","article-title":"Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012\u20132017","volume":"24","author":"Estabrook","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2025120206225485300_dkaf375-B9","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1093\/jac\/dkab279","article-title":"Investigation of mechanisms responsible for decreased susceptibility of aztreonam\/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019","volume":"76","author":"Mendes","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225485300_dkaf375-B10","doi-asserted-by":"publisher","first-page":"e01443-17","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225485300_dkaf375-B11","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2147\/IDR.S315384","article-title":"In vitro activity of meropenem-vaborbactam versus other antibiotics against carbapenem-resistant Escherichia coli from southeastern China","volume":"14","author":"Huang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2025120206225485300_dkaf375-B12","doi-asserted-by":"publisher","first-page":"e00603-20","DOI":"10.1128\/mBio.00603-20","article-title":"Global trends in proteome remodeling of the outer membrane modulate antimicrobial permeability in Klebsiella pneumoniae","volume":"11","author":"Rocker","year":"2020","journal-title":"mBio"},{"key":"2025120206225485300_dkaf375-B13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1099\/jmm.0.045799-0","article-title":"Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile","volume":"61","author":"Wozniak","year":"2012","journal-title":"J Med Microbiol"},{"key":"2025120206225485300_dkaf375-B14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1128\/AAC.01585-15","article-title":"Role of the outer membrane and porins in susceptibility of \u03b2-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam","volume":"60","author":"Pag\u00e8s","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225485300_dkaf375-B15","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirty-Third Edition: M100","author":"CLSI","year":"2023"},{"key":"2025120206225485300_dkaf375-B16","doi-asserted-by":"publisher","first-page":"107363","DOI":"10.1016\/j.ijantimicag.2024.107363","article-title":"Geographic differences in susceptibility profiles of potential non-class B carbapenemase-producing Enterobacterales isolates against ceftazidime-avibactam, meropenem-vaborbactam, colistin, amikacin, gentamicin, and tigecycline: data from the Antimicrobial Testing Leadership and surveillance, 2018\u20132022","volume":"64","author":"Jean","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2025120206225485300_dkaf375-B17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s12879-018-3436-7","article-title":"Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum \u03b2-lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia","volume":"18","author":"Zeynudin","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2025120206225485300_dkaf375-B18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bjid.2013.03.012","article-title":"Molecular epidemiology of CTX-M producing Enterobacteriaceae isolated from bloodstream infections in rio de janeiro, Brazil: emergence of CTX-M-15","volume":"17","author":"Seki","year":"2013","journal-title":"Braz J Infect Dis"},{"key":"2025120206225485300_dkaf375-B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/1040841X.2012.691460","article-title":"Epidemiology and genetics of CTX-M extended-spectrum \u03b2-lactamases in Gram-negative bacteria","volume":"39","author":"Zhao","year":"2013","journal-title":"Crit Rev Microbiol"},{"key":"2025120206225485300_dkaf375-B20","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1128\/JCM.01112-06","article-title":"Widely distributed and predominant CTX-M extended-spectrum \u03b2-lactamases in Amsterdam, The Netherlands","volume":"44","author":"al Naiemi","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2025120206225485300_dkaf375-B21","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1128\/AAC.00099-14","article-title":"Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents","volume":"58","author":"Almaghrabi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225485300_dkaf375-B22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1128\/AAC.01275-10","article-title":"Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence","volume":"55","author":"Tsai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225485300_dkaf375-B23","doi-asserted-by":"publisher","first-page":"e0251594","DOI":"10.1371\/journal.pone.0251594","article-title":"\u03b2-lactam resistance associated with \u03b2-lactamase production and porin alteration in clinical isolates of E. coli and K. pneumoniae","volume":"16","author":"Khalifa","year":"2021","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3345\/64527350\/dkaf375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3345\/64527350\/dkaf375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:58Z","timestamp":1764674578000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3345\/8276585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf375","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,7]]}}}